Pfizer (PFE) insider buying

Healthcare · Drug Manufacturers - General · Market cap $159.3B

20 open-market purchases of PFE by Pfizer's executives and directors since May 2025, worth $0 in total, from SEC Form 4 filings.

The most recent: Gilbert Ray Cisneros, Jr. bought — on February 10, 2026.

The biggest buyer over the period is Gilbert Ray Cisneros, Jr.: 6 purchases, $0.

By year

YearPurchasesValue
20262$0
202518$0

Biggest buyers

InsiderBuysValue
Gilbert Ray Cisneros, Jr.
6$0
Ro Khanna
10$0
Lisa C. Mcclain
2$0
Robert Bresnahan, Jr.
2$0

Every purchase

Newest first. From SEC Form 4 filings. Insider buying across the market.

DateInsiderSharesPriceValueFiling
Feb 10, 2026 Gilbert Ray Cisneros, Jr.
0$27.61— —
Feb 10, 2026 Gilbert Ray Cisneros, Jr.
0$27.61— —
Nov 18, 2025 Gilbert Ray Cisneros, Jr.
0$25.45— —
Nov 18, 2025 Gilbert Ray Cisneros, Jr.
0$25.45— —
Aug 4, 2025 Ro Khanna
0$23.56— —
Aug 4, 2025 Ro Khanna
0$23.56— —
Jul 16, 2025 Lisa C. Mcclain
0$24.59— —
Jul 16, 2025 Lisa C. Mcclain
0$24.59— —
Jul 1, 2025 Ro Khanna
0$25.03— —
Jul 1, 2025 Ro Khanna
0$25.03— —
Jun 20, 2025 Ro Khanna
0$23.97— —
Jun 20, 2025 Ro Khanna
0$23.97— —
May 30, 2025 Gilbert Ray Cisneros, Jr.
0$23.46— —
May 30, 2025 Gilbert Ray Cisneros, Jr.
0$23.46— —
May 28, 2025 Ro Khanna
0$23.18— —
May 28, 2025 Ro Khanna
0$23.18— —
May 19, 2025 Ro Khanna
0$23.01— —
May 19, 2025 Ro Khanna
0$23.01— —
May 15, 2025 Robert Bresnahan, Jr.
0$22.57— —
May 15, 2025 Robert Bresnahan, Jr.
0$22.57— —
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PFE.
Open PFE in Investingly

Questions

Are Pfizer insiders buying the stock?

20 open-market purchases of PFE by Pfizer's executives and directors since May 2025, worth $0 in total, from SEC Form 4 filings. The most recent: Gilbert Ray Cisneros, Jr. bought — on February 10, 2026.

What counts as insider buying here?

Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.

From Pfizer's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.